These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28685558)

  • 1. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes.
    Guarino G; Strollo F; Carbone L; Della Corte T; Letizia M; Marino G; Gentile S
    J Biol Regul Homeost Agents; 2017; 31(2):495-502. PubMed ID: 28685558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; D' Angelo A; Fogari E; Maffioli P
    J Biol Regul Homeost Agents; 2013; 27(3):717-28. PubMed ID: 24152839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses.
    Derosa G; Romano D; D'Angelo A; Maffioli P
    Atherosclerosis; 2015 Mar; 239(1):87-92. PubMed ID: 25577665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus.
    Derosa G; D'Angelo A; Maffioli P
    Clin Nutr; 2016 Oct; 35(5):1091-5. PubMed ID: 26384091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; D'Angelo A; Fogari E; Maffioli P
    Expert Opin Biol Ther; 2013 Nov; 13(11):1495-506. PubMed ID: 23971720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial.
    Derosa G; Romano D; D'Angelo A; Maffioli P
    Phytomedicine; 2015 Feb; 22(2):231-7. PubMed ID: 25765827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes.
    Di Pierro F; Putignano P; Villanova N; Montesi L; Moscatiello S; Marchesini G
    Clin Pharmacol; 2013; 5():167-74. PubMed ID: 24277991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial.
    Ebrahimpour-Koujan S; Gargari BP; Mobasseri M; Valizadeh H; Asghari-Jafarabadi M
    Phytomedicine; 2018 May; 44():39-44. PubMed ID: 29895491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial.
    Ebrahimpour Koujan S; Gargari BP; Mobasseri M; Valizadeh H; Asghari-Jafarabadi M
    Phytomedicine; 2015 Feb; 22(2):290-6. PubMed ID: 25765835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
    Huseini HF; Larijani B; Heshmat R; Fakhrzadeh H; Radjabipour B; Toliat T; Raza M
    Phytother Res; 2006 Dec; 20(12):1036-9. PubMed ID: 17072885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia.
    Di Pierro F; Putignano P; Villanova N
    Acta Biomed; 2018 Jan; 88(4):462-469. PubMed ID: 29350661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the relationship of leptin, high-sensitivity C-reactive protein, adiponectin, insulin, and uric acid to metabolic syndrome in lean, overweight, and obese young females.
    Abdullah AR; Hasan HA; Raigangar VL
    Metab Syndr Relat Disord; 2009 Feb; 7(1):17-22. PubMed ID: 19025443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
    Fogacci F; Grassi D; Rizzo M; Cicero AFG
    Phytother Res; 2019 Apr; 33(4):862-870. PubMed ID: 30632209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial.
    Loftus HL; Astell KJ; Mathai ML; Su XQ
    Nutrients; 2015 Nov; 7(11):9508-22. PubMed ID: 26593941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review.
    Tajmohammadi A; Razavi BM; Hosseinzadeh H
    Phytother Res; 2018 Oct; 32(10):1933-1949. PubMed ID: 30015401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.
    Bouderba S; Sanchez-Martin C; Villanueva GR; Detaille D; Koceïr EA
    J Diabetes; 2014 Mar; 6(2):184-92. PubMed ID: 23953934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.